dMed | Clinipace announce corporate name change to Caidya
SHANGHAI and MORRISVILLE, N.C., October 3, 2022 – dMed |Clinipace, the established clinical research organization serving global innovators, such as biotechs, announced today that it is changing its corporate name to Caidya (KAY-dee-uh).
Bringing together decades of expertise, global reach, and knowledge, Caidya offers the market a unique proposition with a clear focus on delivery excellence to help organizations activate the full potential of their science. Combined with the company’s personalized development approach, Caidya offers a compelling option for innovators looking for an elevated customer experience.
and CEO of Caidya, Dr. Lingshi Tan.
Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer
experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical
development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency
and data-driven decision-making.
world. The Caidya group of companies includes Clinipace, Inc. Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately
held company, whose investors include entities located in the People’s Republic of China (PRC), and which may be subject to PRC laws and regulations that
differ from those of the United States. dMedClinical’s investor group are part of a best-in-class shareholder group which includes leading global venture capital and
VP, Global Marketing, Caidya